Trius Therapeutics, Inc. (TSRX)
-NasdaqGM 7.60 
0.17(2.19%) 4:00PM EDT|After Hours
:
7.60 0.00 (0.00%) 4:31PM EDT
| Prev Close: | 7.77 |
|---|
| Open: | 7.79 |
|---|
| Bid: | 7.50 x 7500 |
|---|
| Ask: | 8.25 x 100 |
|---|
| 1y Target Est: | 12.64 |
|---|
| Beta: | 0.91 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 7.51 - 7.90 |
|---|
| 52wk Range: | 4.41 - 8.50 |
|---|
| Volume: | 895,279 |
|---|
| Avg Vol (3m): | 867,177 |
|---|
| Market Cap: | 363.83M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.56 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tapat TheStreet(Wed 7:00AM EDT)
- Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticalsat Seeking Alpha(Thu, May 16)
- TRIUS THERAPEUTICS INC FinancialsEDGAR Online Financials(Wed, May 15)
- Trius Therapeutics: New, Positive Dimension For Investment Outlookat Seeking Alpha(Mon, May 13)
- Trius Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With DaptomycinGlobeNewswire(Mon, May 13)
- Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013at Seeking Alpha(Mon, May 13)
- Trius Therapeutics initiated with a Buy at Guggenheimtheflyonthewall.com(Fri, May 10)
- Trius Therapeutics Remains One Of Our Best IdeasZacks(Wed, May 8)
- TRIUS THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Trius Therapeutics Remains One Of Our Best IdeasZacks Small Cap Research(Wed, May 8)
- Trius Therapeutics Reports First Quarter 2013 Financial ResultsGlobeNewswire(Tue, May 7)
- The Antibiotic Bubble -- A Quest For Continued Antibiotic Effectivenessat Forbes(Tue, May 7)
- TRIUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExEDGAR Online(Tue, May 7)
- Jim Cramer: Buy Wells Fargo, Radian Group, and These 3 Solid Stocksat Wall St. Cheat Sheet(Mon, May 6)
- Cramer's Top Stock Picks: BRK.B FB TSRXat TheStreet(Sat, May 4)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 19.50 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.39 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.34 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Trius Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibiotics for serious infections.
View More